{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"16.8","value":"3.6"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"3.6","value":"1.8"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"18.1","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"PFS, evaluated using Kaplan-Meier methods, defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Disease progression assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression.","dispersionType":"Full Range","groups":[{"description":"Phase I, Dose Level 1 in recurrent/metastatic (R/M) Human Papillomavirus Vaccine (HPV) associated cancers (cohort 1). Arm 1A: Monotherapy HPV vaccine, Dose escalation. HPV vaccine at 1x10\\^11 Viral Particles (VP).","id":"OG000","title":"Phase I Cohort 1, Arm 1A, Dose Level 1"},{"description":"Phase I, Dose Level 2 in recurrent/metastatic (R/M) Human Papillomavirus Vaccine (HPV) associated cancers (cohort 1). Arm 1A: Monotherapy HPV vaccine, Dose escalation. HPV vaccine at 5x10\\^11 Viral Particles (VP).","id":"OG001","title":"Phase I Cohort 1A, Arm 1A, Dose Level 2"},{"description":"Phase I in recurrent/metastatic (R/M) Human Papillomavirus Vaccine (HPV) associated cancers (cohort 1). Arm 1B: Combination: HPV vaccine at recommended phase 2 dose (RP2D) as determined at completion of Arm 1A plus bintrafusp alfa 1200 mg. HPV vaccine at 5x10\\^11 Viral Particles (VP).","id":"OG002","title":"Phase I Cohort 1, Arm 1B, Dose Level 2"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Date of first treatment to date of disease progression or death (any cause), an average of 6 months","title":"Phase I: Progression-free Survival Time (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}